Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Despite the established cardiovascular benefits of ARNI, its renoprotective effects in chronic kidney disease (CKD) have not been fully elucidated. We investigated its effects on blood pressure (BP), eGFR slope, and proteinuria in hypertensive CKD patients.
We retrospectively analyzed CKD patients switched from renin–angiotensin system (RAS) inhibitors to ARNI and treated for ≥6 months (n=84). The eGFR slope was calculated using linear regression and mixed-effects models. Changes in BP—home BP (HBP) and office BP (OBP)—as well as eGFR slope and urinary protein-to-creatinine ratio (UPCR) were assessed overall and by subgroups (nephrosclerosis [NS], diabetic kidney disease [DKD], baseline eGFR <30 vs ≥30 mL/min/1.73 m²). ΔeGFR slope was regressed against post-treatment home systolic BP (HSBP), categorized as <130 (A), 130–139 (B), ≥140 mmHg (C). A mixed model evaluated the interaction of time, treatment, and post-HSBP.
Mean age 72 ± 11 years; 64% men. NS 37%, DKD 25%, CGN 19%, others 19%. CKD G2 5%, G3a 13%, G3b 24%, G4 45%, G5 13%. Baseline Cre 2.09 ± 1.00 mg/dL, eGFR 29 ± 15 mL/min/1.73 m², UPCR 1.9 ± 2.3 g/gCr. ARNI dose 185 ± 127 → 208 ± 58 mg/day (follow-up 435 ± 167 days); SGLT2i use 48%. Overall:HBP 136 ± 12/78 ± 12 → 130 ± 10/74 ± 9 mmHg (both p<0.05); OBP 150 ± 19/78 ± 17 → 140 ± 18/73 ± 13 mmHg (both p<0.05). eGFR slope −3.67 ± 0.34 → −1.39 ± 0.41 mL/min/1.73 m²/yr (p<0.05); UPCR 2.0 ± 2.4 → 2.0 ± 2.5 (p=0.73). Subgroups: NS (n=31): HBP 134 ± 12/78 ± 13 → 130 ± 9/73 ± 9 (p=0.06/p=0.05); OBP 150 ± 18/80 ± 17 → 138 ± 17/73 ± 12 (both p<0.05); eGFR −3.60 ± 0.64 → −0.85 ± 0.75 (p<0.05).DKD (n=21): HBP 143 ± 14/76 ± 13 → 134 ± 12/73 ± 11 (p<0.05/p=0.29); OBP 152 ± 23/77 ± 16 → 142 ± 20/71 ± 11 (p=0.09/p=0.06); eGFR −4.73 ± 0.75 → −3.55 ± 0.93 (p=0.12). eGFR ≥30 (n=35): HBP 136 ± 13/80 ± 12 → 129 ± 11/78 ± 9 (p<0.05/p=0.36); OBP 148 ± 18/81 ± 19 → 136 ± 17/76 ± 14 (p<0.05/p=0.06); eGFR −2.85 ± 0.52 → −0.51 ± 0.77 (p<0.05). eGFR <30 (n=49): HBP 136 ± 12/78 ± 11 → 130 ± 10/72 ± 9 (both p<0.05); OBP 151 ± 21/76 ± 15 → 144 ± 18/72 ± 11 (p<0.05/p=0.07); eGFR −4.25 ± 0.49 → −2.02 ± 0.54 (p<0.05). ΔeGFR slope correlated negatively with post-HSBP (β = −0.20, p<0.05, R² = 0.10). By post-HSBP group: A (n=41) −3.58 ± 0.43 → 0.41 ± 0.57 (p<0.05); B (n=28) −3.15 ± 0.53 → −3.64 ± 0.69 (p=0.41); C (n=15) −5.04 ± 1.35 → −4.96 ± 1.55 (p=0.93); ANOVA p<0.05. The mixed model also showed a significant three-way interaction (time × treatment × post-HSBP, β = −0.19, p<0.05).
ARNI improved BP and eGFR slope in CKD, with consistent effects except in DKD. Improvement was associated with lower post-HSBP, suggesting that BP reduction under ARNI contributes to renoprotection. ARNI provides a potent antihypertensive effect while preserving eGFR through balanced dilation of both afferent and efferent arterioles. These findings indicate that ARNI safely lowers blood pressure even in advanced stages of CKD and may play a beneficial role in slowing CKD progression.
